QureCraft Innovations’ Post

Discover BiTrial's global presence from our series showcasing the countries where we operate. The next country we’re introducing is Armenia. 🌍 This country offers numerous advantages we can successfully leverage in the field of clinical research. ✅👇 📅 Eurasian Economic Union (EEU) Member Since 2015: Armenia's membership in the EEU has been instrumental in bolstering its healthcare infrastructure, with continuous government investments driving improvements. 📝 Regulatory efficiency: Achieving complete regulatory approval in about 40 days, Armenia demonstrates impressive efficiency despite not being an EU member country. 👥 High enrollment rates: Armenia has a diverse patient population with a strong willingness to participate in clinical studies, contributing to high enrollment rates. 👨⚕️ Skilled medical professionals: The country boasts a growing number of well-trained, skilled medical professionals and researchers, ensuring high-quality clinical trials. 💰 Cost-effective trials: Conducting clinical trials in Armenia can be significantly more cost-effective compared to many Western countries, making it an attractive location for research. 🌐  Visit our website to learn more about our global operations and comprehensive CRO services!  www.bitrial.hu #bitrial #clinicalresearch #armenia #globalpresence #patientrecruitment #cro #fullservicecro #medicalsupport

🌍 **Maintaining Quality in Clinical Trials Across Africa** 🌍 At **Evanjo**, we believe that conducting clinical trials in Africa doesn't just expand access—it sets the stage for **high-quality, impactful research**. Our commitment to **quality assurance** is unwavering, and here’s how we maintain the highest standards: 🔬 **How We Ensure Quality:** - **Experienced and Verified Sites**: We partner with **pre-screened, verified, and experienced trial sites** across Africa. Each site is selected based on strict criteria including **compliance with international standards**, infrastructure quality, and proven experience in clinical trials. - **Qualified Staff**: Our sites are staffed with skilled professionals who understand the intricacies of running successful, high-standard trials, from patient recruitment to data collection. - **Rigorous Monitoring**: We implement continuous quality control, conducting regular audits and performance reviews to ensure trials are executed in line with global **Good Clinical Practice (GCP)** guidelines. - **Diverse Patient Recruitment**: By utilizing Africa’s vast population of naïve patients, we generate accurate, unbiased data for **more reliable results**. At Evanjo, our goal is not only to make Africa a hub for clinical trials but to set a **benchmark in quality** that meets and exceeds global expectations. Let’s discuss how we can support your next clinical trial. please reach out to info@evanjo-med.com #ClinicalTrials #Africa #CRO #QualityResearch #GCP #HealthcareInnovation #Evanjo #GlobalHealth

Europe's peronalised medicines sector boosted by Sino-EU PerMed project The Sino-EU PerMed project, launched in January 2020, is a bi-regional consortium of six partners from governmental, funding and research organisations to promote personalised medicine cooperation between Europe and China. The project was set up as part of a concerted larger effort by the European Commission to increase international collaboration to promote personalised medicine and was devised to engage China in the International Consortium on Personalised Medicine [ICPerMed] - an EU Member States driven initiative and advance the implementation of the Strategic Research and Innovation Agenda on personalised medicine. This Euractiv report explains the purpose of the project, what it set out to achieve, and the expected outcomes. https://lnkd.in/duUzMuZK #PublicHealth #Europe #StayInformed #StayEmpowered

Sino-EU personalised medicines project, Europe bridging a data divide The project was set up as part of a concerted larger effort by the European Commission to increase international collaboration to promote personalised medicine and was devised to engage China in the International Consortium on Personalised Medicine [ICPerMed] - an EU Member States driven initiative and advance the implementation of the Strategic Research and Innovation Agenda on personalised medicine. The main outcomes of the project can be summarized as obtaining a clearer overview of the research and innovation landscape on personalised medicine in China; a better understanding of the main opportunities and hurdles in the development and implementation of personalised medicine cooperation; as well as establishing contacts with the key stakeholders, with whom we have initiated a science, technology and policy dialogue. Gianni D'Errico: In parallel with the Sino-EU Permed project we have launched the European Partnership on Personalised Medicine, which gathers 59 Partners and will invest close to €400 million in personalised medicine over the next years. https://lnkd.in/daW7vKcQ #PublicHealth #Europe #StayInformed #StayEmpowered

Are the Nordics for clinical trials still attractive?    For many reasons, I would say “Yes”!  They are small countries but with a strong biopharma industry, tradition, and high level of expertise as well as dedication and interest in the scientific contributions of clinical trials.  So, while you’re looking at locations for early phase trials, Phase I – II, in almost any indications, the Nordics really could be the place to do succeed. Top level Phase I units for healthy volunteer trials, major hospitals for patient trials, and great SMOs for later phase trials to boost recruitment. KOL’s and highly motivated investigators and site staff, focusing on science and their patients – also interested and enthusiastic to participate! These are just a few of the key strengths and attraction to taking your research to the Nordics.   Want to discover more, contact Union Development, and let’s investigate and design your Nordic BESTFIT Solution. #clinicaltrials #clinicalresearch #drugdevelopment

Governmental Affairs and Market Access (GAMA) team in Baltics is led by Sonata Matuleviciene. The team across all 3 countries is driven by one common purpose to 𝐮𝐧𝐥𝐨𝐜𝐤 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬’ 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐛𝐞𝐬𝐭-𝐢𝐧-𝐜𝐥𝐚𝐬𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. Sonata shares: “Populations are aging, which is driving increased human and financial costs of treating cardiovascular, oncological and rare diseases. However, healthcare in the Baltics is consistently receiving funds below the EU average from GDP, suggesting that it is not a primary focus for our governments. Healthcare systems are already struggling and under-financed. Health is the foundation of a #sustainable and prosperous society, yet quality and timely healthcare remains out of reach for too many people. Time to act is now”.   Only by collaborating with key stakeholders and decision-makers across sectors, we can help to ‘future proof’ health systems to develop and deliver the next new wave of innovation and strengthen health system’s resilience. However, #collaboration at scale and pace is essential and no single entity can manage it alone. AstraZeneca has the know-how and the will to be a #partner for both public as well as other like-minded private sector representatives to find solutions and act as “One Voice” for a healthier future of the people living in Estonia, Latvia and Lithuania. #AZBaltics #LifeAtAZBaltics #WhatScienceCanDo

Our latest report on Rethinking Clinical Trial Country Prioritization details the shifts in global clinical trial landscapes from 2019, focusing on how different regions have adapted in hosting Phase I-III clinical trials. Notably, Europe has seen a decline in its share across nearly all trial segments, while China has experienced growth in almost all areas, except biosimilars. This regional shift underscores the dynamic nature of clinical trial distribution worldwide, highlighting significant increases in certain regions and steady declines in others. For industry professionals, understanding these trends is crucial for ensuring the effective allocation of resources. 🔗 Explore the implications of these shifts by accessing the full report: https://bit.ly/3N2tpHQ. #ClinicalTrials #PharmaResearch #GlobalHealth

On this International Clinical Trials Day, Metrics Research applauds all stakeholders who contribute to developing and advancing clinical trials in Pakistan. This video features our CEO, Murtaza Hussain, and General Manager, Muhammad Sharib Syed, discussing Pakistan's evolving clinical trial landscape & the role of Metrics Research in promoting clinical trials in the country, achieving successful patient-centred outcomes and transforming healthcare globally. We look forward to continued advancements through research in Pakistan with innovation & excellence. #Internationalclinicaltrialsday #Clinicaltrialsday2024 #ClinicalTrialsinPakistan #ClinicalResearchProfessionals #healthcare #medicalresearch #MetricsResearch #ContractResearchOrganization #CRO #ResearchInnovationExcellence

Exciting shifts are happening in Argentina’s clinical trials landscape. With policy enhancements and a growing emphasis on regulatory efficiency, the country is quickly becoming a hotspot for medical device research. These developments open new doors for innovation and collaboration in Latin America. Argentina is not just leveraging its unique demographics but also reinforcing a framework that supports speedy yet thorough approvals. This change spells opportunity for CROs and sponsors aiming to tap into diverse patient populations while maintaining rigorous standards of safety and efficacy. As we navigate these promising changes, how can we capitalize on Argentina's evolving environment to drive impactful clinical trials? Let's share insights and strategies that could redefine success stories in medical device testing across Latin America! #ClinicalResearch #MedicalDevices #InnovationInHealthcare

The need for representative participant populations in clinical trials has long been discussed, but a heightened awareness of the lack of inclusion in research has emerged in recent years. Read this International Clinical Trials (Samedan Ltd) article by Belinda Paez Russell, Dir. of Recruitment Strategy at Headlands Research, to learn how strategic, multifactorial planning can help achieve inclusive clinical trial enrollment. #ClinicalTrials #ClinicalTrialEnrollment #InclusiveClinicalTrials #HeadlandsResearch https://lnkd.in/eMPv_-ys